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The induction of donor-specific transplant tolerance is one of the main goals of modern 
immunology. Establishment of a mixed chimerism state in the transplant recipient has 
proven to be a suitable strategy for the induction of long-term allograft tolerance; how-
ever, current experimental recipient preconditioning protocols have many side effects, 
and are not feasible for use in future therapies. In order to improve the current mixed chi-
merism induction protocols, we developed a non-myeloablative bone-marrow transplant 
(NM-BMT) protocol using retinoic acid (RA)-induced alloantigen-specific Tregs, clinically 
available immunosuppressive drugs, and lower doses of irradiation. We demonstrate 
that RA-induced alloantigen-specific Tregs in addition to a NM-BMT protocol generates 
stable mixed chimerism and induces tolerance to allogeneic secondary skin allografts in 
mice. Therefore, the establishment of mixed chimerism through the use of donor-specific 
Tregs rather than non-specific immunosuppression could have a potential use in organ 
transplantation.
Keywords: alloreactive regulatory T cells, mixed chimerism, transplant tolerance, organ transplantation, non-
myeloablative conditioning
inTrODUcTiOn
Achieving transplant tolerance as a means to improve the outcome of organ transplantation is one of 
the main challenges of modern immunology. Current immunosuppressive drug regimens succeed in 
preventing acute organ rejection; however, they fail to induce long-term operational tolerance and 
cannot prevent chronic rejection (1–3).
The generation of mixed chimerism has become an attractive alternative to achieving the induc-
tion of long-term tolerance to allografts (4, 5). Mixed chimerism is defined as the coexistence of 
donor and recipient hematopoietic cell precursors in a pre-conditioned allogeneic bone-marrow 
transplant (BMT) recipient (4–6). There is robust evidence showing that the induction of mixed 
chimerism allows the generation of alloantigen-specific tolerance in animal models (7–11) and 
humans (12–15).
Abbreviations: APCs, antigen-presenting cells; BMT, bone-marrow transplant; NM-BMT, non-myeloablative bone-marrow 
transplantation; RA, retinoic acid; RA-iTregs, retinoic acid-inducible regulatory T cells; TBI, total body irradiation; Tregs, 
regulatory T cells.
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However, the generation of mixed chimerism requires 
myeloablative preconditioning protocols that can be risky and 
ethically unfeasible for application on patients who are eligible 
for a transplant. Different types of regimens have been designed 
to reduce the myeloablation necessary for the establishment of 
mixed chimerism (16, 17). Many of them use non-myeloablative 
doses of total body irradiation (TBI) (18, 19), either alone or in 
combination with the administration of immunosuppressive 
drugs (20), depleting antibodies (21–23), and/or co-stimulation 
blockers (7, 24). The inhibition of CD40/CD40L pathway is criti-
cal to induce mixed chimerism without T cell depletion (7, 25, 
26). Nevertheless, CD40/CD40L pathway inhibition has been 
associated with thromboembolic complications (27, 28), and its 
approval for clinical use remains doubtful.
The use of cellular therapy, which mediates immune toler-
ance in an antigen-specific manner, may reduce the degree of 
immunosuppression or co-stimulation blockade necessary for 
the establishment of mixed chimerism to a minimum. Regulatory 
T cells have been widely studied for their potential use in this 
type of therapies. These cells prevent autoimmune and inflam-
matory diseases, regulate immune responses against viral, 
bacterial, or parasitic infections, and can also restrain responses 
directed toward tumors or transplanted tissues (29–33). Two 
different types of Tregs have been described; natural Tregs 
CD4 + CD25 + Foxp3 + (nTregs), which are generated in the 
thymus, and induced Tregs CD4 +  CD25 +  Foxp3 + (iTregs), 
which develop in the periphery from naïve CD4 + T cells. Both 
subsets of Tregs mediate their suppression in an antigen-specific 
manner (34).
Regulatory T cells have been used in several different cell 
therapies to treat experimental pathological models. These cells 
have been shown to prevent graft-versus-host disease (35), delay 
allograft rejection (36–38), and also provide protection for auto-
immune disease therapies (39). Most of the protocols expand the 
existing pool of Treg cells, through the use of CD3 + CD28+ beads 
to obtain sufficient number of Treg to use in cellular therapy (40, 
41). However, the polyclonal expansion of Tregs could generate a 
pool of cells with a wide spectrum of specificities.
Our group (41, 42) and others (35) have previously demon-
strated the role of retinoic acid (RA) in enhancing the differ-
entiation of CD4 + T cell to iTregs (42, 44–46). We developed 
a protocol to generate iTregs from naïve T cells in presence of 
allogeneic CD11c-enriched antigen-presenting cells (APCs), RA, 
and TGF-β. These, allogeneic RA-iTregs express several immuno-
suppressive molecules on the surface, have a potent suppressive 
capacity, show a stable phenotype, and avoid alloantigen-specific 
skin transplant rejection (42).
In this study, we sought to determine whether allogeneic 
RA-iTregs could improve current preconditioning protocols 
of BMT to establish mixed chimerism and induce donor-
specific tolerance (25, 43). To test this, we generated a new 
 non- myeloablative bone-marrow transplant (NM-BMT) protocol 
using allogeneic RA-iTregs, together with Rapamycin, Abatacept 
(CTLA4Ig), combined with low-dose TBI. This protocol allows 
the generation of stable mixed chimerism that induces tolerance 




Six to 12-week-old C57BL/6 (Donor, H-2b), BALB/c, and B10.BR 
(Recipients, H-2d and H-2k, respectively) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME, USA). Animals 
were kept in an animal facility under standard housing guide-
lines. The animal work was carried out under the institutional 
regulation of Fundacion Ciencia & Vida and was locally approved 
by an ethical review committee.
antibodies and reagents
The characterization of Tregs and the analysis of different 
populations in blood from NM-BMT mice were performed by 
flow cytometry using the following antibodies: anti-H2Kb FITC 
(AF6.88.6), anti-H2Kd PE (SF1-1.1), anti GITR FITC (DTA-1), 
anti-CD19 APC-H7 (1D3), and anti-CD25 FITC (7D4) from BD 
Pharmingen (Franklin Lakes, NJ, USA); anti-CD4 FITC (RM4-5), 
anti-CD4 PE-Cy5 (RM4-5), anti-CD25 PE (PC61.5), anti-CD25 
APC (PC61, 5), anti-CD8a PE-Cy7 (53-6.7), anti-GR1 PE-Cy7 
(GL7), anti-FoxP3 PE-Cy7 (FJK-16s), anti-CD4 APC (6K1.5), 
anti-CD3 APC (17A2), and anti-CD16/32 (2.4G2) from eBiosci-
ence (San Diego, CA, USA); and anti-CD4 PE (RM4-5) and anti-
F4/80 APC-Cy7 (BM8) from BioLegend (San Diego, CA, USA).
Recombinant human TGF-β1 was purchased from eBiosci-
ence (San Diego, CA, USA), mouse recombinant IL-2 from R&D 
System (Minneapolis, MN, USA), and RA from Sigma-Aldrich 
(St Louis, MO, USA).
non-Myeloablative Bone-Marrow 
Transplant
BALB/c mice were irradiated with high-energy photons using 
the Oncor Impression PlusLinear Accelerator (Siemens, Munich, 
Germany). Mice received 3 Gy of TBI 1 day before BMT (day −1).
Groups of age-matched recipient mice received three doses 
of Rapamycin (LC Laboratories, Woburn, MA, USA) (5  mg/
kg) at day −1, 0, and 2 (25). At day 0, BALB/c mice received a 
dose of 20 × 106 bone-marrow (BM) cells from C57BL/6 mice 
with or without 2.2 × 106 of RA-iTregs generated from BALB/c 
mice. On day 2, recipient mice received a single dose (24  mg/
kg) of Abatacept (CTLA4Ig) (Orencia, Bristol-Myers Squibb 
Pharmaceuticals, Princeton, NJ, USA).
generation and isolation of retinoic  
acid-induced regulatory T cells
Alloantigen-specific RA-iTregs were generated following 
published protocols (43, 44). Briefly, RA-iTregs were gener-
ated by stimulating naive T cells from BALB/c mice (sorted as 
CD4 + CD25−CD62LhiCD44low) in the presence of C57BL/6 
APCs plus RA (10 nM), TGF-β (2 ng/ml), and IL-2 (10 ng/ml). 
After 6 days of culture, RA-iTregs were further purified by cell 
sorter as CD4+ CD25hi cells using a FACSAria II Cell Sorter (BD 
Bioscience, San Diego, CA, USA). The purity of the RA-iTregs 
preparation was always over 95%. Polyclonal RA-iTregs were 
generated by stimulating naive T cells from BALB/c mice in the 
presence of BALB/c APCs plus anti-CD3 mAb RA (10 nM), TGF-
beta (2 ng/ml), and IL-2 (10 ng/ml).
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The phenotype of RA-iTreg was determined by flow cytometry 
(FACS Canto II, BD Bioscience, San Diego, CA, USA). The analy-
sis was carried out using the FlowJo version 8.7 software (Tree 
Star Inc. Ashland, OR, USA). Intracellular Foxp3 staining was 
done using the Foxp3 staining Kit (eBioscience, San Diego, CA, 
USA) following the manufacturer’s instructions.
skin Transplantation
For skin transplant experiments, we used C57BL/6 (H-2b) mice 
as skin donors and BALB/c (H-2d) mice as transplant recipients. 
Skin transplantation was performed 4 weeks post BM transplant. 
The recipient mice were anesthetized with 3% XEVORane 
(Abbot, Buenos Aires, IL, Argentina). Full thickness tail skin from 
mismatched C57BL/6 mice of ~1 cm × 1 cm was transplanted 
on the left lateral flank of recipient mice. Mice were bandaged 
for 10 days, and the acceptance or rejection of the graft was ana-
lyzed by macroscopic visual inspections at short time intervals. 
Rejection was determined when transplanted skin formed a dry 
scar (44, 45, 49, 50).
chimerism analysis by Flow cytometry
To evaluate mixed chimerism, we measured the presence of 
donor MHC-I positive cells in blood and expressed it as the 
percentage of donor MHC-I positive cells over total leukocyte 
lineage. The percentages of the different donor populations were 
determined by labeling the cells with anti-CD3, anti-CD4, anti-
CD8, anti-CD19, anti-GR1, and anti-F4/80 in combination with 
donor MHC-I antibody. We performed the analyses on 3, 4, 7, 10, 
13, and 16 weeks after NM-BMT.
elisPOT assays
Splenocytes were recovered from BALB/c recipients 110 to 
120  days after skin graft transplantation. These cells were re-
stimulated for 24 h with previously irradiated (30 Gy) allogeneic 
(C57BL/6) or syngeneic (BALB/c) splenocytes. To measure the 
frequency of IFN-γ, IL-4-, and IL-17-producing cells, we used the 
mouse ELISPOT Ready-SET-go Kit (eBioscience San Diego, CA, 
USA) according to the manufacturer’s instructions. The frequen-
cies of cytokine-secreting cells were expressed as the number of 
cytokine-producing cells per 1 × 105 responder cells. All assays 
were done in triplicate.
In vitro Mlr suppression assay
CD4 + CD25− responder T cells (5 × 104) were sorted from BALB/c 
mice and labeled with CellTrace Violet dye (Life Technologies). As 
stimulator cells, we used 1 × 105 previously irradiated splenocytes 
(30  Gy) from C57BL/6 (allogeneic), B10.BR (third-party) or 
BALB/c (syngeneic) mice. The responder and stimulator cells were 
co-cultured at different ratios with CMTMR-labeled RA-iTreg 
or with anti-CD3 mAb. After 5 days, CellTrace Violet dilution in 
responder cells was analyzed by flow cytometry.
statistical analysis
Statistical analyzes were performed using Prism program for 
Macintosh, version 4.0b (GraphPad Software Inc.). In order 
to establish the statistical distribution of the results, we used 
the Shapiro–Wilk normality test. Depending on the sampling 
distribution, a non-parametric Mann–Whitney test, a parametric 
Student’s t-test, or one-way ANOVA was used. The graft survival 
curves are shown using a Kaplan–Meier analysis and the statisti-
cal significance was estimated by LogRank test. p-values ≤0.05 
were considered statically significant. The data are presented as 
mean ± error standard (SEM).
resUlTs
Donor-specific ra-iTreg Together with a 
nM-BMT Protocol induces stable Mixed 
chimerism
In a previous study, we generated donor-specific retinoic acid-
induced Tregs (RA-iTregs) and used these cells to prevent skin 
allograft rejection in an immunodeficient Rag1−/− mouse 
model (42). However, it remained to be established whether 
these donor-specific RA-iTregs were also able to generate mixed 
chimerism and allow transplantation tolerance in immuno-
competent mice. To test this, we designed a NM-BMT protocol 
that may be translated to clinical use. This NM-BMT protocol 
consists of 3  Gy TBI (at day −1), three doses of Rapamycin 
(5 mg/kg at day −1, 0, and 2), and a single dose of Abatacept 
(CTLA4Ig) (24  mg/kg at day +2). Additionally, some of the 
recipient mice received a single dose of RA-iTregs at day 0 (see 
diagram on Figure 1A).
Next, we sought to study the ability of allospecific Tregs to 
induce mixed chimerism. For this, we stimulated naive T cells 
obtained from BALB/c mice (H-2d) with allogeneic APCs from 
C57BL/6 mice (H-2b) in the presence of TGF-β, RA, and IL-2. 
Figure S1A in Supplementary Material shows that RA-iTregs 
generated after 6 days of culture express several markers related 
to Treg function such as CTLA4, LAG3, CD73, CD39, GARP, 
CD103, and GITR. Then, we tested whether these RA-iTregs 
could specifically inhibit the allogeneic response. As shown in 
Figure S1B in Supplementary Material, RA-iTregs specifically 
inhibited the proliferation of T cells cultured with C57BL/6 
APCs but not cultures done with third-party APCs (B10.
BR). Moreover, allogeneic RA-iTregs are more efficient than 
polyclonal RA-iTregs at inhibiting the proliferation of T cells 
in mixed leukocyte reactions (Figure S2 in Supplementary 
Material).
To study the ability of these allospecific RA-iTregs in promot-
ing mixed chimerism, donor H-2Kb cells in peripheral blood 
samples of NM-BMT mice were assessed by flow cytometry. As 
shown in Figure 1B, mice receiving RA-iTregs presented donor-
derived (H-2Kb+) cells compared with the group that did not 
receive RA-iTregs. This result demonstrates that RA-iTregs can 
generate mixed chimerism in our NM-BMT protocol.
To evaluate the stability of mixed chimerism generated by a 
single dose of RA-iTregs, we determined over time the presence 
of H-2Kb cells in peripheral blood of mice. Figure 1C shows that 
the group that did not receive RA-iTregs presented lower levels 
of chimerism, disappearing by 7 weeks after BMT. By contrast, 
mice treated with RA-iTregs displayed a statistically significant 
percentage of mixed chimerism up to 16 weeks post BMT, indi-
cating that a single dose of RA-iTregs is sufficient to induce a 
stable mixed chimerism.
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Next, we evaluated reconstitution of the chimera with 
multi-lineage donor leukocytes. For this, we analyzed CD4+ 
and CD8+ T cell subsets, B lymphocytes (CD19+), monocytes 
(F4/80+), and granulocytes (GR-1+) by flow cytometry in blood 
samples at different time points post NM-BMT (Figures S3A,B 
in Supplementary Material). We observed increasing percentages 
of T lymphocytes, with a similar contribution from CD4+ and 
CD8+ T cells. The levels of B cells were maintained over time 
and represented a substantial percentage of total chimerism. 
Furthermore, we observed granulocyte and monocyte reconstitu-
tion. However, in contrast to lymphoid cells, myeloid cells showed 
a decrease over time. Therefore, we observed that the mice sub-
jected to NM-BMT in combination with RA-iTregs repopulated 
all cellular hematopoietic lineages from donor precursors.
ra-iTregs Together with nM-BMT Prolong 
allograft survival
To determine whether chimeras obtained with RA-iTregs induce 
tolerance mechanisms in BALB/c recipient mice, we performed 
allogeneic skin grafts using C57BL/6 mice as skin donors. 
Transplants were done 4  weeks after the initiation of the non-
myeloablative protocol. We separated recipient mice into three 
groups: non-treated mice, NM-BMT mice, and RA-iTreg treated 
NM-BMT mice. Figure 2A shows the presence of skin and black 
hair at the site of the transplant 100  days after skin transplant 
FigUre 1 | alloantigen-specific ra-iTregs allow the generation of stable mixed chimerism in nM-BMT mice. (a) Schematic representation of NM-BMT 
regimen. BALB/c mice received NM-BMT regimens that consisted in the administration of low doses of irradiation (3 Gy of TBI at day −1), together with co-stimulation 
blockade with Abatacept (CTLA4Ig) (24 mg/kg at day 2), and three doses of Rapamycin (5 mg/kg at days −1, 0, and 2). At day 0, mice received 20 × 106  
bone-marrow cells from C57BL/6 mice and 2.2 × 106 BALB/c RA-iTreg cells or PBS. (B) Chimerism at 3 weeks post-transplantation was analyzed by the presence of 
H-2Kb positive cells in blood. (c) Kinetics of mixed chimerism, analyzed as the presence of H-2Kb positive cells in peripheral blood samples from NM-BMT mice 
treated with (▫) or without (•) RA-iTregs. The statistical one-way ANOVA test was used. Bars represent the SE. The data represent seven independent experiments. 
Rapa, Rapamycin; Aba, Abatacept; RA-iTregs, retinoic acid-induced Tregs cells; BMT: Bone-marrow transplantation. ***p < 0.0001; **p < 0.001; *p < 0.01.
in RA-iTreg-treated mice. Mice that received only NM-BMT 
quickly rejected the allograft as shown by the scar at the site of 
operation. Figure  2B shows that Treg-treated NM-BMT mice 
showed a significant increase (p < 0.0001) in the survival of the 
transplanted skin, exceeding 100  days post-transplant, without 
the need for any additional immunosuppression. Therefore, 
mixed chimeras generated with the combination of NM-BMT 
and RA-iTregs induce tolerance mechanisms that allow the 
acceptance of allogeneic skin grafts.
ra-iTregs Together with nM-BMT inhibit 
allogeneic-induced Th1 cellular 
responses
The main factors involved in organ rejection are cellular immune 
responses mediated by Th1 and Th17 cells (46, 47). It has been 
reported that the induction of mixed chimerism promotes Th2 
responses that favor alloimmune tolerance (53). Thus, we inves-
tigated by ELISPOT assays the type of alloimmune response pro-
duced by RA-iTregs-treated NM-BMT mice at the end of the skin 
transplant protocol. For this, splenocytes from transplanted mice 
were co-cultured for 24 h with syngeneic or allogeneic splenocytes 
on pre-coated ELISPOT plates to analyze IFN-γ-, IL-4, and IL-17 
secreting cells. We used as controls splenocytes from NM-BMT 
mice that rejected the skin transplant. As shown in Figure 3, we 
observed a strong Th1 response, as measured by IFN-γ secretion, 
FigUre 2 | nM-BMT mice treated with ra-iTregs have a prolonged 
allogeneic skin graft survival. Skin transplants were performed using 
C57BL/6 mice as donors of tail skin in untreated BALB/c mice (BALB/c) (▴) 
(n = 3); bone-marrow-transplanted BALB/c mice (BALB/c NM-BMT) (•) 
(n = 13); or bone-marrow-transplanted BALB/c plus RA-iTregs (BALB/c 
NM-BMT + RA-iTreg) (▫) (n = 17) as receptors. (a) Image of skin transplant at 
day 50 post-transplant. (B) Kaplan–Meier survival analysis of skin allograft 
transplantation for 100 days post-transplant. LogRank Statistical test 
(comparison of survival curves) was performed. p-value <0.05. The results 
represent four independent experiments.
FigUre 3 | Th1 allogeneic immune response is inhibited in nM-BMT 
mice that received ra-iTregs. One hundred days after skin transplant, 
splenocytes from NM-BMT mice treated with or without RA-iTregs were 
co-cultured with APC from BALB/c (syngeneic) or C57BL/6 (allogeneic) mice. 
IFN-γ, IL-17, and IL-4 cytokine secretion was measured by ELISPOT. Bars 
show the SE. The Mann–Whitney–Wilcoxon statistical test for non-parametric 
distributions was used. The results represent two independent experiments.
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only when splenocytes from NM-BMT are stimulated with alloge-
neic splenocytes. We observed that RA-iTregs-treated NM-BMT 
had a significant decrease in IFN-γ secreting cells comparable to 
the level found in syngeneic cocultures (p = 0.008). We did not see 
any significant IL-4 or Il-17 cytokine secretion in all conditions, 
indicating that Th2 and Th17 cellular responses do not medi-
ate allograft rejection in our setting. These results suggest that 
peripheral tolerance mechanisms induced in RA-iTreg-treated 
NM-BMT mice effectively abolish Th1 alloimmune responses.
chimeric Mice exhibit Donor-Derived 
regulatory T cells
To study the mechanism of tolerance induction in RA-iTreg-
treated NM-BMT mice, we evaluated the presence of CD4 +   
CD25 + FoxP3+ Tregs derived from donor precursors cells (H-2b) 
in these mice. As shown in Figure 4, 100 days after skin transplant, 
we found donor-derived H-2b + CD4 + CD25 + FoxP3+ Tregs 
in blood and spleen of NM-BMT mice treated with RA-iTregs. 
When we correlated the presence of donor Tregs with skin 
transplant acceptance or rejection (Figure 4B), we observed that 
some mice that accepted allogeneic skin transplant presented 
donor Tregs in spleen and blood. However, we could not detect 
donor Tregs in blood and spleen in mice that rejected allogeneic 
skin.
DiscUssiOn
In this work, we developed a protocol using RA-iTregs to induce 
mixed chimerism. Here, we combine RA-iTregs with a NM-BMT 
avoiding the need of CD40/CD40L signaling inhibition. This 
NM-BMT protocol consisted of a low dose of TBI (3 Gy), three 
doses of the immunosuppressive drug Rapamycin, and one dose 
of co-stimulation blockade using Abatacept (CTLA4Ig). We dem-
onstrate that the use of RA-iTregs with this non-myeloablative 
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preconditioning setting promotes mixed chimerism and signifi-
cantly extends the survival of allogeneic skin graft.
CD4 + CD25 + Foxp3+ Tregs have been used previously to 
generate mixed chimerism and alloimmune tolerance in two dif-
ferent reports (25, 43). Joffre’s group induced mixed chimerism 
by using donor-specific Tregs obtained through the expansion of 
splenic CD4 + CD25 + Foxp3+ cells with allogeneic dendritic 
cells and IL-2 in combination with 5 Gy TBI (43). Despite the 
positive results they obtained, the use of high-dose irradiation is 
critical and limits future application in humans (48, 49). In the 
second report, the authors tested different types of polyclonal 
Tregs: nTregs, iTregs, and FoxP3 transduced Tregs, in their ability 
to induce mixed chimerism (25). These authors induced mixed 
chimerism by using these Tregs in combination with Rapamycin, 
co-stimulation blockade with Abatacept, and anti-CD154 as non-
myeloablative preconditioning, thereby avoiding the use of radia-
tion. This work demonstrates that natural or induced Tregs allow 
the generation of mixed chimerism and transplantation tolerance 
without cytoreductive conditioning (25). Although these results 
are promising, translation into clinical use in humans faces two 
problems; first, the use of anti-CD154 is restricted to experimen-
tal procedures only, and second, the use of polyclonal Tregs may 
inhibit immune responses against infections or may cause higher 
rates of cancer. Here, we sought to improve these preconditioning 
protocols so that it could be translated into clinical application in 
FigUre 4 | De novo generation of donor Tregs in nM-BMT mice receiving ra-iTregs. (a) One hundred days after skin transplant, donor-derived Tregs were 
analyzed in peripheral blood and spleen in NM-BMT mice treated with RA-iTregs. (B) Percentage of CD4 + Foxp3 + H-2Kb+ in peripheral blood and spleen in mice 
that accept (n = 6) or reject (n = 7) the allogeneic skin transplant. Bars represent the SE. The Mann–Whitney–Wilcoxon statistical test was used. The results 
represent two independent experiments.
humans. The protocol we developed is donor specific and avoids 
the use of anti-CD154, thus, diminishing the risks associated with 
its use and allowing its future translation to human trials (27).
The goal of transplant immunology is to provide specific-donor 
immunosuppression, and this specificity could be achieved by 
alloantigen-specific Tregs. Here, we show that RA-iTregs express 
immunosuppressive molecules and specifically inhibit the prolif-
eration of effector T cells that recognized the same alloantigen. 
The latter observation is in agreement with previous work from 
our group (42, 44), where we demonstrated that RA-iTreg cells 
showed alloantigen-specific immunosuppressive capacity in 
a skin allograft model in immunodeficient mice. In support of 
this, work by Joffre’s group show selective grafting of allogeneic 
bone marrow from the specificity of Tregs, whereas bone marrow 
from a third strain was rejected (43, 48). Moreover, in a previous 
report, we have shown that RA-iTreg cells are stable in time when 
adoptively transferred and present an unbiased homing capabil-
ity (42). Thus, alloantigen-specific Tregs may establish specific 
tolerance while maintaining immune responsiveness to foreign 
antigens.
A recent article published by Wekerle’s group reports that 
rapamycin and CTLA4Ig synergize to induce stable mixed 
chimerism (50). Their strategy to induce mixed chimerism is 
very similar to ours except that they give mice an extra dose of 
CTLA4Ig and they use 2 Gy of TBI. Importantly, they did not use 
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Tregs to induce chimerism. In our hands, we obtain stable mixed 
chimerism only when we add RA-iTregs. The differences between 
Wekerle’s and our results may be due, in part, to the combination 
of donor-recipient mouse strains used in both studies. Although 
we achieved some chimerism without Tregs, it was only transient 
since it was lost by 7  weeks. On the other hand, Wekerle and 
collaborators induce donor-specific tolerance to heart allografts 
but they do not succeed with skin allograft as we did, which is 
considered to be more stringent than the heart transplant. Here, 
we developed a powerful long-term operational tolerance proto-
col to donor-specific skin allograft, surpassing minor and major 
antigens barriers to produce mixed chimerism induction.
The protocol we used in this work to induce mixed chimerism 
allows the reconstitution of all hematopoietic cell populations fre-
quently found in peripheral blood from the donor. The percent-
age of lymphocytes remains stable or increases over time while 
macrophages and granulocytes tend to decrease. The reasons why 
myeloid cells change over time have not been elucidated; how-
ever, the establishment of tolerance has been associated with the 
presence of donor T cells (51). It has been shown that tolerance 
induced by mixed chimerism can be reversed by depleting CD4+ 
T cells (52, 53). Thus, the decrease in the myeloid populations 
could be an irrelevant factor in the establishment of tolerance 
although this should not be entirely disregarded. Although we 
could not achieve a 100% graft survival, here, we demonstrate 
that mixed chimerism induced by RA-iTregs extends the life of 
the allogeneic skin transplant. As transplant tolerance correlates 
with the level of chimerism (54, 55), we could speculate that the 
percentage of graft survival could be increased if the transplant 
is performed at earlier times following the BMT.
Mice that received our conditioning protocol of NM-BMT 
together with RA-iTregs exhibited donor-derived Tregs. These 
cells were detected in blood and spleen 120 days after the trans-
plant. Previous reports where mixed chimerism was obtained 
through non-myeloablative preconditioning and depletion of 
donor CD25+ cells in the transplanted BM, showed no transplant 
acceptance (56). Moreover, the depletion of donor or recipient 
Foxp3+ cells following skin and heart transplant induces the 
loss of allogeneic tolerance mediated by mixed chimerism (57). 
Although we observed a positive correlation between the presence 
of donor-derived Tregs and the acceptance of skin transplant, this 
correlation was not statistically significant. A complete evalua-
tion of this donor Tregs in other tissues of mice that accepted 
or rejected their allografts are needed in order to determine the 
origin and contribution of these cells in transplant tolerance.
The translation of this protocol to induce donor-specific toler-
ance in humans is possible since several protocols to differenti-
ate human CD4+ T cells into Tregs have been described (58). 
Therefore, the establishment of mixed chimerism through the 
use of donor-specific Tregs rather than general or non-specific 
immunosuppression could constitute a reasonable alternative in 
organ transplantation.
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